Featured Paper of the Month – February 2025
Published in Molecular Psychiatry by Rani Richardson, Leandro Vendruscolo, and Lorenzo Leggio of the NIDA IRP.
Summary
Alcohol use disorder (AUD) and binge drinking are highly prevalent public health issues. The stomach-derived peptide ghrelin, and its receptor, the growth hormone secretagogue receptor (GHSR)—both of which are expressed in the brain and periphery— are implicated in alcohol-related outcomes. We previously found that systemic and central administration of GHSR antagonists reduced binge-like alcohol drinking, whereas a ghrelin vaccine did not. Thus, we hypothesized that central GHSR drives binge-like alcohol drinking independently of peripheral ghrelin. To investigate this hypothesis, we antagonized β1-adrenergic receptors (β1ARs) using atenolol (peripherally restricted) and metoprolol (brain permeable). Both compounds robustly decreased plasma ghrelin levels. Also, direct brain administration of atenolol had no effect on peripheral endogenous ghrelin levels. However, only metoprolol, but not atenolol, decreased binge-like alcohol drinking. These results suggest that GHSRs rather than peripheral endogenous ghrelin is involved in binge-like alcohol drinking. They also suggest that central β1ARs drive binge-like alcohol drinking. Thus, GHSRs and β1ARs represent possible targets for therapeutic intervention for AUD, including the potential combination of drugs that target these two systems.
Publication Information
In: Mol Psychiatry, 2024, ISSN: 1476-5578.